3,4-Ethylenedioxy-N-methylamphetamine (EDMA) is a member of the entactogen drug family belonging to the methamphetamine class. In essence, it is an analog of MDMA, where the characteristic methylenedioxy ring has been replaced by an ethylenedioxy call. The synthesis of EDMA is credited to Alexander Shulgin. In his notable work “PiHKAL,” the recommended dosage for EDMA falls within the range of 150 to 250 milligrams, with an expected duration of effects lasting approximately 3 to 5 hours.
As described by Shulgin, the effects of EDMA are relatively subtle, often characterized by a minimal threshold response that includes sensations of paresthesia, nystagmus, and hypnagogic imagery. These effects are typically observed with few to no additional discernible outcomes.
Scientific investigations have further revealed that EDMA functions as a serotonin-releasing agent without inducing neurotoxicity. However, its potency in this regard is moderately reduced compared to MDMA, and it exhibits minimal influence on dopamine release.

IUPAC name
CAS Number133787-66-3 
PubChem CID24257269
Chemical and physical data
Molar mass207.273 g·mol−1


  • What is EDMA?
  • EDMA, or 3,4-Ethylenedioxy-N-methylamphetamine, is a chemical compound that belongs to the entactogen drug class, sharing a resemblance to methamphetamine. It is recognized as an analog of MDMA, characterized by the replacement of the methylenedioxy ring with a methylenedioxy ring.
  • Who synthesized EDMA, and when was it first developed?
  • Alexander Shulgin, a prominent figure in the field of psychopharmacology, initially synthesized EDMA. The compound’s creation is credited to his work.
  • What are the recommended dosage and duration of MDMA’s effects?
  • As detailed in Shulgin’s book “PiHKAL,” the suggested dosage range for EDMA typically falls between 150 and 250 milligrams. The duration of its effects is expected to last approximately 3 to 5 hours.
  • What kind of effects does EDMA produce?
  • EDMA is known for producing relatively subtle effects, often characterized by a minimal threshold response. This includes sensations of paresthesia (tingling or numbness), nystagmus (involuntary eye movement), and hypnagogic imagery (vivid mental images when falling asleep), with few to no additional discernible outcomes.
  • Is EDMA neurotoxic, like some other entactogens?
  • Scientific research suggests that EDMA acts as a non-neurotoxic serotonin-releasing agent. While it shares similarities with MDMA, it is notably less potent in its serotonin-releasing effects and has minimal impact on dopamine release.
  • Is EDMA a controlled substance?
  • The legal status of EDMA can vary by location. In some regions, it may be regulated as a controlled substance due to its structural and chemical similarity to other controlled substances. It is crucial to be aware of and adhere to local drug laws and regulations.
  • Is EDMA safe for use?
  • The safety of using EDMA is not well-established, and its use is not approved for any medical or therapeutic purposes. The potential risks and effects of EDMA use can vary from person to person. It is essential to exercise caution and consider the possible consequences.
  • Are there harm reduction measures for EDMA use?
  • Practicing harm reduction strategies, such as using substance testing services and starting with lower doses, can help minimize risks associated with EDMA use. However, the safest approach is to avoid using such substances altogether.


  1. Ann Shulgin; Alexander Shulgin (1991). “Pihkal: A Chemical Love Story.” Published by Transform Press. ISBN 0-9630096-0-5. This seminal work by Ann and Alexander Shulgin, known as “Pihkal,” is a captivating exploration of their experiences with psychedelic compounds and the chemistry behind them.
  2. McKenna DJ, Guan XM, Shulgin AT (March 1991). “Differential Effects of 3,4-Methylenedioxyamphetamine (MDA) Analogues on Synaptosomal Release of 3H-Dopamine and 3H-5-Hydroxytryptamine.” This scientific study, conducted in March 1991, investigates the varying impacts of MDA analogs on the release of 3H-dopamine and 3H-5-hydroxytryptamine in synaptosomes. [Reference: Pharmacology Biochemistry and Behavior, 38(3), 505–12]

Leave a Comment

Your email address will not be published. Required fields are marked *